{
    "clinical_study": {
        "@rank": "111060", 
        "arm_group": {
            "arm_group_label": "Brimonidine tartrate", 
            "arm_group_type": "Experimental", 
            "description": "One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7)."
        }, 
        "brief_summary": {
            "textblock": "To characterize the plasma pharmacokinetics and safety profile of brimonidine following a\n      single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution\n      0.025% for 7 days in healthy, adult subjects."
        }, 
        "brief_title": "Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperemia", 
        "condition_browse": {
            "mesh_term": "Hyperemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  have ocular health within normal limits.\n\n          -  have blood (hematology, blood chemistry) and urine analysis within normal limits.\n\n          -  have a body weight within 15% of ideal weight\n\n        Exclusion Criteria:\n\n          -  have known contraindications or sensitivity to the use of any of the investigational\n             drug(s) or their components, or any other medications required by the protocol;\n\n          -  have any active systemic or ocular disorder other than refractive disorder.\n\n          -  have presence of any abnormality of the lids, ocular surface, or lacrimal duct system\n             that in the Investigator's opinion could affect ophthalmic drop absorption.\n\n          -  have a history of chronic alcohol consumption.\n\n          -  consume alcohol and/or caffeine or xanthine containing products within 48 hours prior\n             to dosing at Visit 1 or anticipated use during the study.\n\n          -  have a history of tobacco, nicotine, or nicotine containing product use within the\n             last year prior to Visit 2;\n\n          -  have significant weight change (over 10 pounds) within the 60 days prior to Visit 2;\n\n          -  have blood donation or equivalent blood loss of 450 ml or more, within 60 days prior\n             to Visit 2;\n\n          -  have an abnormal blood pressure (defined as \u2264 90 or \u2265 160 (systolic) measured in mmHg\n             or \u2264 60 or \u2265 100 (diastolic) measured in mmHg);\n\n          -  have intraocular pressure (IOP) that is less than 5 mmHg or greater than 22 mmHg or\n             have a normal IOP with a diagnosis of glaucoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039765", 
            "org_study_id": "863/13-100-0007"
        }, 
        "intervention": {
            "arm_group_label": "Brimonidine tartrate", 
            "intervention_name": "Brimonidine tartrate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Brimonidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Ocular Redness", 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14609"
                }, 
                "name": "Bausch & Lomb, Incorporated"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in Healthy, Adult Subjects.", 
        "overall_official": {
            "affiliation": "ORA, Inc.", 
            "last_name": "Joseph Ciolino, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 1.", 
                "measure": "Plasma Levels", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Visit 2)"
            }, 
            {
                "description": "Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 2.", 
                "measure": "Plasma Levels", 
                "safety_issue": "No", 
                "time_frame": "Day 2 (Visit 3)"
            }, 
            {
                "description": "Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 7.", 
                "measure": "Plasma Levels", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (Visit 4)"
            }, 
            {
                "description": "Blood samples will be collected for the determination of brimonidine in plasma at the specified time points on Day 8.", 
                "measure": "Plasma Levels", 
                "safety_issue": "No", 
                "time_frame": "Day 8 (Visit 5)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039765"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Visual acuity testing should be done with best correction at 10ft", 
                "measure": "Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 1)"
            }, 
            {
                "description": "Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of  0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.", 
                "measure": "Slit Lamp Biomicroscopy", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 1)"
            }, 
            {
                "description": "Intraocular Pressure measured at baseline Day 8 (Visit 5)", 
                "measure": "Intraocular Pressure", 
                "safety_issue": "No", 
                "time_frame": "Day 8 (Visit 5)"
            }, 
            {
                "description": "Blood samples will be collected for hematology and blood chemistry parameters at Baseline (Visit 1)", 
                "measure": "Hematology and Blood Chemistry Analysis", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 1)"
            }, 
            {
                "description": "Urine sample will be collected for urinalysis at Baseline (Visit 1)", 
                "measure": "Urinalysis", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 1)"
            }, 
            {
                "description": "Visual acuity testing should be done with best correction at 10ft", 
                "measure": "Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Visit 2)"
            }, 
            {
                "description": "Visual acuity testing should be done with best correction at 10ft", 
                "measure": "Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (Visit 4)"
            }, 
            {
                "description": "Visual acuity testing should be done with best correction at 10ft", 
                "measure": "Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "Day 8 (Visit 5)"
            }, 
            {
                "description": "Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of  0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.", 
                "measure": "Slit Lamp Biomicroscopy", 
                "safety_issue": "No", 
                "time_frame": "Day 1 (Visit 2)"
            }, 
            {
                "description": "Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of  0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.", 
                "measure": "Slit Lamp Biomicroscopy", 
                "safety_issue": "No", 
                "time_frame": "Day 7 (Visit 4)"
            }, 
            {
                "description": "Lid and lid margin erythema and swelling, conjunctival erythema/hyperemia and chemosis will be graded on a scale of  0 - 4. with 0=normal and 4=marked. Half grade measurements will be accepted for erythema/hyperemia.", 
                "measure": "Slit Lamp Biomicroscopy", 
                "safety_issue": "No", 
                "time_frame": "Day 8 (Visit 5)"
            }, 
            {
                "description": "Intraocular Pressure measured at baseline (Visit 1)", 
                "measure": "Intraocular Pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Visit 1)"
            }, 
            {
                "description": "Blood samples will be collected for hematology and blood chemistry parameters at Day 8 (Visit 5)", 
                "measure": "Hematology and Blood Chemistry Analysis", 
                "safety_issue": "No", 
                "time_frame": "Day 8 (Visit 5)"
            }, 
            {
                "description": "Urine sample will be collected for urinalysis at Day 8 (Visit 5)", 
                "measure": "Urinalysis", 
                "safety_issue": "No", 
                "time_frame": "Day 8 (Visit 5)"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "collaborator": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}